AB Science provides a summary of the key points of the web

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
AB Science provides a summary of the key points of the web conference held on 08 April 2016 on masitinib in the treatment of amyotrophic lateral sclerosis.

Masitinib in Amyotrophic Lateral Sclerosis (ALS)

Summary of Webcast

PARIS, April 11, 2016 (GLOBE NEWSWIRE) --  AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), provides a summary of the key points of the web conference held on 08 April 2016 with key opinion leaders on masitinib in the treatment of amyotrophic lateral sclerosis.

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease and Charcot disease, is a life-threatening neurological disease that causes muscle weakness, disability and eventually death. Only around 10% of patients live past 10 years with 80% of patients die within 5 years. ALS represents a high unmet medical need with an estimated combined target population in the USA and EU of 50,000 patients.

The only drug registered in this indication is Riluzole, which was registered in 1996. There has been no advance in availability of effective therapeutic agents over the last 20 years. All studies in this indication failed.

Design of study AB10015 The study was initiated as a phase 2, transformed at early stage into a phase 3. The study remained blinded. A resampling was done while endpoints and hypothesis on treatment effects remained similar. The study followed a classical design and used the endpoints recommended by the guideline.

Study AB10015 is a blinded, placebo controlled, 3-treatment arms (randomisation 1:1:1), testing 2 doses of masitinib (3 and 4.5 mg/kg/day) in add-on to riluzole, versus placebo plus riluzole. Treatment duration is 48 weeks. Efficacy assessment was based on endpoints validated by regulatory authorities.

  • Primary endpoint: ALSFRS-R (Amyotrophic Lateral Sclerosis Functional Rating Scale)
  • Secondary endpoints : FVC (Forced Vital Capacity) , CAFS (Combined Assessment of Function and Survival)
  • Supportive endpoints : ALS-AQ40 (Quality of life), survival

The planned enrolment was 381 patients, with a pre-planned futility analysis with 30% of patients enrolled treated for 48 weeks, and a pre-planned interim analysis with 50% of patients enrolled treated for 48 week.

The interim analysis was based on 192 patients in 3 arms, equivalent to 64 patients per arm. The objective of the interim analysis was to conclude on efficacy prior to completion of the study and to discuss with regulatory authorities about early filing based on interim result, or to adjust the sample size if the study was under-powered. The protocol did not specify to stop the study in case interim analysis was successful.

The primary hypothesis was to detect a difference in the mean change of ALSFRS-R between placebo group and masitinib group after 48 weeks with a 0.0311 significance level, using a Pocock alpha spending method. Efficacy analyses were conducted in a stepwise manner. Fixed sequence method was used to control the global family-wise error rate at the 0.0311 level for the primary analysis for each dose. Secondary analyses (FVC, CAFS, ALS-AQ40, OS) were performed only if primary analysis was significant, therefore at a 0.05 significance level. The dataset was analysed in the ITT population, using LOCF method (last observation carried forward).

Status of study AB10015 Patients were enrolled in sites in Europe, Argentina and Canada, (not USA).

The patient recruitment was completed in December 2015 with 392 patients. Recruitment at interim and final analysis was made 2/3 in Europe and 1/3 outside Europe.

Next steps AB Science will initiate discussion with EMA and FDA regarding the possibility to file for marketing authorization.

Outcome of interim analysis The study is not stopped at this time for the following reason.

  • Obtain more mature survival data
  • Obtain long term safety data
  • Protect the scenario of conditional approval with condition being that analysis with 392 patients at week 48 is confirmatory

The recruitment is completed therefore there is no impact on recruitment. Follow-up data will be available in Q1 2017.

To protect the follow-up phase of the study, no data can be disclosed at this time such as providing exact p-value, treatment effect or dose effect which is considered by the authorities as a potential bias.

All precautions were taken to ensure that the follow-up part of the study is unbiased. A procedure was documented describing who performed the analysis and who accessed the interim analysis results. Furthermore, it is not feasible for investigators or patients to predict if treatment received is masitinib+riluzole or placebo+riluzole based on adverse events of masitinib or riluzole. Indeed, most frequent adverse events with masitinib are gastro-intestinal disorders (diarrhea, nausea, vomiting) and skin and subcutaneous disorders (rash, pruritus, erythema) and rarely neutropenia. Riluzole generates the same disorders (diarrhea, nausea, vomiting, and rash, pruritus, erythema) and rarely neutropenia.

The phase 2/3 was a success at the interim analysis based on pre-specified primary endpoint on ALSFRS-R. ALSFRS-R is a validated (1) rating score for monitoring the progression of disability in patients with ALS, which takes into account both quality of life and survival. Primary analysis in ITT population is successful with p-value <1%. P-value <1% can be considered as a substantial evidence of efficacy based on guideline for registration under single pivotal study. The hypothesis of the study was to detect a difference of around 3 points in ALSFRS-R at week 48 between the two treatment arms with a 0.0311 significance level. The placebo in the ALS studies typically deteriorates by 1 point per month, so 12 points in 12 months. The objective was therefore to detect a 25% difference in deterioration, a difference considered clinically relevant. Given the p-value was below 1%, this means that the treatment effect was clinically significant.

The primary analysis was supported by all sensitivity analyses. The first method of sensitivity analysis was based on reasons for discontinuation and was positive. Different methods of missing data imputation based on the reasons of discontinuation were used, in line with "Guideline. EMA/CPMP/EWP/1776/99 Rev. 1". The second method of sensitivity analysis was based on multiple imputation and was successful. Multiple imputation is a statistical technique based on regression model permitting to analyze data sets that are incomplete because of missing entries, such as discontinuation. Values at week 48 for patients who discontinued are calculated from the values of patients who reach week 48. The simulation is repeated 500 times.

The phase 2/3 was a success at the interim analysis based on the forced vital capacity (FVC) (1) . FVC is the vital capacity (VC) measured when the patient is exhaling with maximal speed and effort. Significant benefit confirmed with sensitivity analyses with different data censoring method based on reason of discontinuation.

The phase 2/3 was a success at the interim analysis based on CAFS (2) . CAFS ranks each patient against all other patients based on survival time and change in ALSFRS-R score. CAFS is a recognized as a valid endpoint by FDA.

The phase 2/3 was a success at the interim analysis based on ALS-AQ40. ALS-AQ40 is a questionnaire to assess the quality of life.

There was no bias at the interim analysis

  • There was no bias in baseline characteristics
  • There was no unexpected placebo effect
  • There was no bias due to center effect or country effect.

The safety profile of masitinib in combination with riluzole appeared acceptable.

  • The Independent Data and Safety Monitoring Board (DSMB) reviewed safety data frequently during the study and always recommended the continuation of the study on this basis.
  • The frequency of adverse events was comparable between the two treatment arms (for the first dose tested)
  • The frequency of serious adverse events was comparable between the two treatment arms (for the first dose tested)
  • The frequency of adverse events leading to treatment discontinuation was comparable between the two treatment arms (for the first dose tested)
  • One isolated case autoimmune hepatic toxicity was reported. Masitinib can generate ALT increase and riluzole appears to have potential hepatotoxic effects with cytolytic and cholestatic effects and may cause liver dysfunction.
  • ALS is a life threatening disease

Furthermore, the safety profile of masitinib is well characterized, The safety database includes over 4,000 patients enrolled in various clinical studies, including more than 2,500 exposed to masitinib.

Study rationale

  • Glia is a key therapeutic target in ALS. Indeed, there is a proliferation of microglia and aberrant microglia in ALS patient, and dysfunctional glial cells contribute to progressive motoneuron death in ALS.
  • Masitinib targets microgia via M-CSFR1. The IC50 of masitinib on M-CSFR1 is 90nM and masitinib dose of 3 mg/kg/day or 4.5 mg/kg/day provide a concentration above the IC50.
  • In-vivo and in-vitro data show that masitinib decreases glia proliferation, astrocytes migration and potently reduces microgliosis (accumulation of microglia cells) in SOD1 G93A rats. In SOD1 G93A rats, masitinib reduces motor neuron death and protects motor neuron atrophy.
  • Masitinib generated positive preclinical results at therapeutic dose for human. Masitinib delayed the onset of symptoms and improves grip strength in ALS SOD1 G93A mice. In two randomized, blinded trials, masitinib increased the survival of SOD1 G93A rats whether given immediately at the onset of gait abnormalities or 7 days after gait onset.

The phase 2/3 study with masitinib suggests that microglia is a relevant target in ALS.

Intellectual property IP rights for masitinib are secured in ALS until 2028 and potentially until 2036 based on a recently filed phase 3 patent. Masitinib has been granted orphan drug status in ALS by FDA (filing at EMA pending). This status provides exclusivity of 7 years  in USA and 10 years in Europe.

Targeted population with masitinib in ALS ALS incidence is high but prevalence is low due to the rapid fatal outcome of the disease. There are approximately 50,000 people with ALS in the European Union and in the US, with more than 16,000 new cases diagnosed each year in Europe and in the US.

Commercial approach in case of registration In case of registration, a stand-alone strategy for commercialization in the USA and Europe would be pursued.

About masitinib Masitinib is a new orally administered tyrosine kinase inhibitor that targets mast cells and macrophages, important cells for immunity, through inhibiting a limited number of kinases. Based on its unique mechanism of action, masitinib can be developed in a large number of conditions in oncology, in inflammatory diseases, and in certain diseases of the central nervous system. In oncology due to its immunotherapy effect, masitinib can have an effect on survival, alone or in combination with chemotherapy. Through its activity on mast cells and microglia and consequently the inhibition of the activation of the inflammatory process, masitinib can have an effect on the symptoms associated with some inflammatory and central nervous system diseases and the degeneration of these diseases.

About AB Science Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a  class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short term survival or rare or refractory to previous lines of treatment in cancers, inflammatory diseases, and central nervous system diseases, both in human and animal health.

AB Science has developed a proprietary portfolio of molecules and the Company's lead compound, masitinib, has already been registered for veterinary medicine in Europe and in the USA. The company is currently pursuing twelve phase 3 studies in human medicine in first-line and second-line GIST, metastatic melanoma expressing JM mutation of c-Kit, multiple myeloma, metastatic colorectal cancer, metastatic prostate cancer, pancreatic cancer, mastocytosis, severe asthma uncontrolled by oral corticosteroid, Alzheimer's Disease, progressive forms of multiple sclerosis, and amyotrophic lateral sclerosis. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB).

Further information is available on AB Science's website: www.ab-science.com

This document contains prospective information. No guarantee can be given as for the realization of these forecasts, which are subject to those risks described in documents deposited by the Company to the Authority of the financial markets, including trends of the economic conjuncture, the financial markets and the markets on which AB Science is present.

AB Science - Financial Communication & Media Relations investors@ab-science.com

1   http://www.ema.europa.eu/docs/en_GB/document_...00199241.p

2  A new endpoint for ALS clinical trials., Berry JD1, Miller R, Moore DH, Cudkowicz ME, van den Berg LH, Kerr DA, Dong Y, Ingersoll EW, Archibald RRY & al 2013

CP Eng http://hugin.info/155655/R/2002216/738844.pdf

HUG#2002216

Scroll down for more posts ▼

Top 10 Most Recent News Articles

DISA Backs Nursing Education With OADN Foundation Push

Updated Category News Views 79

A nursing workforce does not appear by magic when hospitals need it most; somebody has to help students, instructors, and programs survive the long haul before that first shift. DISA's newly announced partnership with the Organization for Associate Degree Nursing and the OADN Foundation is aimed squarely at that unglamorous, essential stretch of the pipeline. For a sector...

Continue Reading
ASU's International Enrollment Lead Carries Real Weight

Updated Category News Views 125

Twenty thousand nine hundred twenty-six international students is not a campus footnote; it is a serious operating force moving through Arizona State University and the state around it. ASU has held the No. 1 spot among U.S. public universities hosting international students for six straight years, and the 2026 Open Doors report puts it No. 2 across public and private...

Continue Reading
Fraud0-FouAnalytics Takes Aim at Legacy Ad Verification

Updated Category News Views 115

Digital ad measurement has spent years grading its own homework, and that little arrangement may finally be getting some daylight. fraud0 and FouAnalytics say their expanded partnership will give advertisers impression-level visibility into where ads actually rendered, whether apparent humans engaged with them, and where wasted Google Ads spend might be recoverable. The...

Continue Reading
Atalanta Takes Formal Verification Into Critical Systems

Updated Category News Views 573

A week of bewildering infrastructure failures is a nasty time to discover nobody can explain the machinery. That was the backdrop for Atalanta CEO and co-founder Anjana Rajan at the National Academies of Sciences, Engineering, and Medicine's Cyber Resilience Forum, which concluded November 20 after two days in Washington. Her central point deserves more attention than the...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 110

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
KONST Pitches Asia GPU Uptime as AI Demand Gets Real

Updated Category News Views 131

GPU racks are easy to admire when the lights are on; keeping them useful at 3 a.m. is where the bruises show. KONST arrived at SC26 in Chicago with a sensible pitch for an AI-infrastructure market that is getting less impressed by shiny hardware lists and more obsessed with whether the thing actually works. Its theme, “24/7 GPUs Delivered in Asia,” puts the emphasis...

Continue Reading
Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 103

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
Sidus Gains Argotec Order, but Investors Need the Math

Updated Category News Views 161

A Real Customer Signal, Minus the Revenue Figure An updated image is the least interesting detail in this release. Sidus Space has landed a purchase order from Argotec Group to manufacture cable assemblies for the HAWK satellite platform, with delivery expected in the first quarter of 2027. That is a legitimate operational win for NASDAQ:SIDU. It brings in a new...

Continue Reading
APEC's Shenzhen Signal Is Bigger Than a Two-Day Summit

Updated Category News Views 100

Shenzhen spent two days trying to turn regional anxiety into a workable agenda. The APEC CEO Summit 2026, held November 17 and 18 at the Qianhai International Convention Center, brought together more than 2,000 political and business leaders from all 21 APEC economies and 13 economies outside the group. That is a serious room, not a ceremonial photo line. Still, investors...

Continue Reading
BON’s Oat Lab Bet Puts Scale and Standards in Focus

Updated Category News Views 32

Oats Meet the Industrialization Problem Oats rarely make a small-cap story more interesting, yet this one has a real business nerve running through it. Bon Natural Life has teamed with China Oat Group to establish a joint laboratory aimed at biomanufacturing high-value, oat-derived natural ingredients. The headline is not simply another research collaboration. The stated...

Continue Reading

Top 5 Most Recently Viewed Articles

Secretariat's Legacy Bottled: Bourbon Honors Belmont Win

Updated Category News Views 28

A Toast to Racing History When you think about groundbreaking victories, Secretariat's name is right up there. Now, they’re bottling that history into bourbon. It's not just any day you get a drink inspired by a 31-length victory. Thoroughbred fans and whiskey lovers, listen up because Thirty-One Lengths Bourbon is bringing Secretariat back into the spotlight....

Continue Reading
China Automotive Systems Achieves Record Revenue in 2024

Updated Category News Views 202

Record Revenue Growth at China Automotive Systems China Automotive Systems, Inc. (NASDAQ: CAAS) has reported a remarkable increase in its revenue for the fiscal year 2024, achieving an all-time high of $650.9 million. This represents a significant 12.9% increase from the previous year's revenue of $576.4 million, demonstrating the company's strength in the competitive...

Continue Reading
Future of Energy Storage: A Market Growth Journey Ahead

Updated Category News Views 271

Understanding the Energy Storage Market Potential The global energy storage sector is on the brink of significant growth, projected to escalate from a value of USD 58.9 billion in 2024 to an astonishing USD 204.8 billion by 2033. This remarkable trajectory represents an impressive compound annual growth rate (CAGR) of 14.8%. As the world leans more heavily towards...

Continue Reading
Celebrated Legal Innovators: Reuben Raucher & Blum Shine Bright

Updated Category News Views 116

Reuben Raucher & Blum Earn Legal Visionary Recognition Boutique law firm Reuben Raucher & Blum (RRB), based in Los Angeles, has recently gained significant recognition for its exceptional legal expertise. Partners Tim Reuben and Stephanie Blum have been celebrated as Legal Visionaries in Business of Law magazine. This award acknowledges their remarkable leadership and...

Continue Reading
Baker Hughes Welcomes Ahmed Moghal as New CFO to Drive Growth

Updated Category News Views 294

Baker Hughes Announces New CFO Appointment HOUSTON and LONDON — Baker Hughes Company (NASDAQ: BKR) has officially appointed Ahmed Moghal as the new Chief Financial Officer. Moghal, who has been instrumental in the organization’s financial strategies as the CFO of Industrial & Energy Technology (IET), steps into this pivotal role immediately. His vast experience within...

Continue Reading